NEOPHARM: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NEOPHARM
Largest movements
- Cash +€6,422
up €6,422 (+7.5%), from €85,307 to €91,729
mainly Net result for the year (+€16,103) and Depreciation (+€5,000)
- Tangible fixed assets -€5,000
no longer reported in 2025 (was €5,000)
- Receivables within one year -€2,030
down €2,030 (-44.2%), from €4,591 to €2,561
- Profit (loss) carried forward +€16,098
up €16,098 (+29.0%), from €55,426 to €71,523
- Other debts -€15,162
down €15,162 (-78.2%), from €19,379 to €4,218
- Tax, wage and social debts -€1,545
down €1,545 (-10.6%), from €14,529 to €12,985
of which Taxes: -€1,806
- Gross operating margin -€8,860
down €8,860 (-24.2%), from €36,671 to €27,811
- Taxes -€1,471
down €1,471 (-21.7%), from €6,785 to €5,314
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €94,958 | €94,350 | -€608 | -0.6% |
| Fixed assets | 21/28 | €5,060 | €60 | -€5,000 | -98.8% |
| Tangible fixed assets | 22/27 | €5,000 | - | -€5,000 | |
| Furniture and vehicles | 24 | €5,000 | - | -€5,000 | |
| Financial fixed assets | 28 | €60 | €60 | = | 0.0% |
| Current assets | 29/58 | €89,898 | €94,290 | +€4,392 | +4.9% |
| Amounts receivable within one year | 40/41 | €4,591 | €2,561 | -€2,030 | -44.2% |
| Trade receivables | 40 | €4,591 | €2,561 | -€2,030 | -44.2% |
| Cash at bank and in hand | 54/58 | €85,307 | €91,729 | +€6,422 | +7.5% |
| Total equity and liabilities | 10/49 | €94,958 | €94,350 | -€608 | -0.6% |
| Equity | 10/15 | €57,426 | €73,523 | +€16,098 | +28.0% |
| Contributions | 10/11 | €2,000 | €2,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €55,426 | €71,523 | +€16,098 | +29.0% |
| Amounts payable | 17/49 | €37,532 | €20,827 | -€16,705 | -44.5% |
| Amounts payable within one year | 42/48 | €37,532 | €20,827 | -€16,705 | -44.5% |
| Trade debts | 44 | €3,624 | €3,625 | +€1 | 0.0% |
| Suppliers | 440/4 | €3,624 | €3,625 | +€1 | 0.0% |
| Taxes, remuneration and social security | 45 | €14,529 | €12,985 | -€1,545 | -10.6% |
| Taxes | 450/3 | €11,789 | €9,983 | -€1,806 | -15.3% |
| Remuneration and social security | 454/9 | €2,740 | €3,001 | +€262 | +9.5% |
| Other amounts payable | 47/48 | €19,379 | €4,218 | -€15,162 | -78.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,301 | €5,000 | -€301 | -5.7% |
| Other operating charges | 640/8 | €1,430 | €1,334 | -€96 | -6.7% |
| Gross operating margin | 9900 | €36,671 | €27,811 | -€8,860 | -24.2% |
| Operating profit (loss) | 9901 | €29,940 | €21,477 | -€8,463 | -28.3% |
| Financial income | 75/76B | - | €4 | +€4 | |
| Recurring financial income | 75 | - | €4 | +€4 | |
| Non-recurring financial income | 76B | - | €4 | +€4 | |
| Financial charges | 65/66B | €47 | €64 | +€17 | +35.6% |
| Recurring financial charges | 65 | €47 | €64 | +€17 | +35.6% |
| Non-recurring financial charges | 66B | €47 | €64 | +€17 | +35.6% |
| Profit (loss) for the period before taxes | 9903 | €29,893 | €21,417 | -€8,476 | -28.4% |
| Income taxes | 67/77 | €6,785 | €5,314 | -€1,471 | -21.7% |
| Profit (loss) for the period | 9904 | €23,107 | €16,103 | -€7,005 | -30.3% |
| Profit (loss) for the period to be appropriated | 9905 | €23,107 | €16,103 | -€7,005 | -30.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.